Sernova (SEOVF) entered into a preclinical research collaboration with AstraZeneca (AZN) to evaluate the use of Sernova’s Cell Pouch System in combination with AstraZeneca’s novel therapeutic cells. AstraZeneca is exploring the use of Sernova’s Cell Pouch System as a potential platform for integration with its development of the next wave of innovative cell therapies for various indications. Under the terms of the collaboration, AstraZeneca will lead and completely fund the development of the cell technologies and pre-clinical activities in conjunction with Sernova. The discovery work is being funded and conducted at AstraZeneca. The preclinical research outcomes will determine the feasibility of potential therapeutic applications and subsequent product development activities between the two companies.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- VGK: 5 Reasons I Like This European ETF
- AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan
- Unusually active option classes on open April 27th
- 3 Best Stocks to Buy Now, 4/27/2023, According to Top Analysts
- AstraZeneca sees FY23 core EPS up high single to low double-digit percentage
